JP2023513156A5 - - Google Patents
Info
- Publication number
- JP2023513156A5 JP2023513156A5 JP2022547671A JP2022547671A JP2023513156A5 JP 2023513156 A5 JP2023513156 A5 JP 2023513156A5 JP 2022547671 A JP2022547671 A JP 2022547671A JP 2022547671 A JP2022547671 A JP 2022547671A JP 2023513156 A5 JP2023513156 A5 JP 2023513156A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- car
- hapten
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969917P | 2020-02-04 | 2020-02-04 | |
| US62/969,917 | 2020-02-04 | ||
| PCT/US2021/016194 WO2021158534A1 (en) | 2020-02-04 | 2021-02-02 | Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513156A JP2023513156A (ja) | 2023-03-30 |
| JP2023513156A5 true JP2023513156A5 (enExample) | 2024-02-09 |
| JP7744914B2 JP7744914B2 (ja) | 2025-09-26 |
Family
ID=77200468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547671A Active JP7744914B2 (ja) | 2020-02-04 | 2021-02-02 | ハプテン標識細胞によりキメラ抗原受容体ｔ細胞を刺激する方法およびそのための組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230172981A1 (enExample) |
| EP (1) | EP4100026A4 (enExample) |
| JP (1) | JP7744914B2 (enExample) |
| KR (1) | KR20220164474A (enExample) |
| CN (1) | CN115397440A (enExample) |
| AU (1) | AU2021216554A1 (enExample) |
| CA (1) | CA3169804A1 (enExample) |
| IL (1) | IL295074A (enExample) |
| WO (1) | WO2021158534A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US12312416B2 (en) * | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| WO2023178073A2 (en) * | 2022-03-15 | 2023-09-21 | Celledit Llc | Use of antigen presenting cells to enhance car-t cell therapy |
| WO2024206913A2 (en) * | 2023-03-31 | 2024-10-03 | Northwestern University | Compositions for antigen-specific immune cell activation |
| WO2024251866A1 (en) * | 2023-06-06 | 2024-12-12 | Danmarks Tekniske Universitet | A synthetic cellular advanced signal adapter (scasa) system |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020004052A1 (en) * | 1990-05-08 | 2002-01-10 | David Berd | Composition comprising a tumor cell extract and method of using the composition |
| PL3560953T3 (pl) * | 2014-12-24 | 2024-05-13 | Autolus Limited | Komórka |
| JP2018532801A (ja) * | 2015-10-30 | 2018-11-08 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 標的化がん療法 |
| CN109789092A (zh) * | 2016-07-13 | 2019-05-21 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| US10617720B2 (en) * | 2016-10-20 | 2020-04-14 | Miltenyi Biotech, GmbH | Chimeric antigen receptor specific for tumor cells |
| EP3336107A1 (en) * | 2016-12-15 | 2018-06-20 | Miltenyi Biotec GmbH | Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor |
| CN110381989A (zh) * | 2016-12-21 | 2019-10-25 | 丹麦技术大学 | 用于免疫细胞操作的抗原呈递支架 |
| US11649288B2 (en) * | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| KR20260026092A (ko) * | 2017-09-19 | 2026-02-25 | 메사추세츠 인스티튜트 오브 테크놀로지 | 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도 |
| WO2019067805A1 (en) * | 2017-09-27 | 2019-04-04 | University Of Southern California | NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY |
| US12312416B2 (en) * | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| KR20210074274A (ko) * | 2018-08-06 | 2021-06-21 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물 |
-
2021
- 2021-02-02 CN CN202180019063.XA patent/CN115397440A/zh active Pending
- 2021-02-02 CA CA3169804A patent/CA3169804A1/en active Pending
- 2021-02-02 IL IL295074A patent/IL295074A/en unknown
- 2021-02-02 EP EP21751276.3A patent/EP4100026A4/en active Pending
- 2021-02-02 US US17/758,960 patent/US20230172981A1/en active Pending
- 2021-02-02 JP JP2022547671A patent/JP7744914B2/ja active Active
- 2021-02-02 AU AU2021216554A patent/AU2021216554A1/en active Pending
- 2021-02-02 KR KR1020227030136A patent/KR20220164474A/ko active Pending
- 2021-02-02 WO PCT/US2021/016194 patent/WO2021158534A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513156A5 (enExample) | ||
| Song et al. | In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) | |
| Kiesgen et al. | Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies | |
| Yeku et al. | Adoptive T-cell therapy for solid tumors | |
| CN113082201B (zh) | 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法 | |
| US20220152150A1 (en) | Mesoporous silica particles compositions for viral delivery | |
| McDermott et al. | Preclinical efficacy of the antibody–drug conjugate CLDN6–23-ADC for the treatment of CLDN6-positive solid tumors | |
| US20230302155A1 (en) | Compositions and methods for in vivo generation of car expressing cells | |
| JP2021513961A5 (enExample) | ||
| JP2019024499A (ja) | 免疫療法のためのエンゲージャー細胞 | |
| JP2021502104A5 (enExample) | ||
| Tordsson et al. | Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma | |
| CN115397440A (zh) | 用半抗原标记细胞刺激嵌合抗原受体t细胞的方法和组合物 | |
| JP2021505637A5 (enExample) | ||
| JP7541390B2 (ja) | 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途 | |
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| Vanhooren et al. | TARP as antigen in cancer immunotherapy | |
| JP2025515324A5 (enExample) | ||
| CN118786142A (zh) | 用于治疗肿瘤的ror1 car或ror1/cd19双car t细胞 | |
| CN107854490A (zh) | 一种经修饰的t细胞及其应用 | |
| Mashayekhi et al. | Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers | |
| KR102562878B1 (ko) | 질환 항원이 융합된 단백질 및 이의 용도 | |
| JP2025512377A5 (enExample) | ||
| Canevari et al. | Approaches to implement bispecific antibody treatment of ovarian carcinoma | |
| Coyne et al. | Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549) |